Introduction
============

The growing threat of antibiotic resistance has contributed to a rapidly increasing interest in phage therapy. Recently, this subject was discussed in detail; in fact, reviews on phage therapy appear almost every month ([@B20]). The first clinical trial of PT performed in accord with Good Medicinal Practice and evidence-based medicine showed a clinically relevant reduction in bacterial burden after 7 days of topical phage application ([@B29]). Hopefully, this and other planned and ongoing trials will lead to the licensing of phage products as anti-infective agents ([@B59]).

Recent progress in studies on phage has provided new insights into the biology of bacterial viruses. Phage may mediate anti-inflammatory and immunomodulating activities that could be relevant in the maintenance of immunological homeostasis ([@B17]). Thus, phage present in our body (a phageome) could protect human health ([@B24]). Furthermore, those studies also suggest the potential of PT in autoimmune diseases and allergy ([@B20]).

Could our phageome and PT also protect us not only from bacterial but also from at least some viral and fungal infections? The treatment of viral infections remains a difficult challenge, whilst the development of biologic therapies has increased with the concurrent increase of their substantial side risk of viral infections ([@B50]). As pointed out, most viral infections lack specific treatment and the need to combat old, emergent and re-emergent viruses is not paralleled by the development of new antivirals ([@B39]). Likewise, invasive fungal infections have been increasing while current antifungal agents have important limitations such as their limited choice, severe toxicity, high cost and emergence of drug resistance ([@B10]; [@B34]; [@B76]). Therefore, alternative and safe anti-fungal agents are also urgently needed.

Drug repurposing, the application of an existing therapeutic to a new disease indication is currently a popular strategy offering the hope for rapid clinical development with fewer risks and a lower cost than *de novo* drug development ([@B13]). Metformin is the first-line treatment for type 2 diabetes that suppresses gluconeogenesis ([@B35]). Recent data indicate that this globally most prescribed antidiabetic medication also functions at the level of the microbiome specifically reducing the abundance of *Bacteroides fragilis* in the intestines, which increases the level of liver bile acids and eventually increases insulin sensitivity. Moreover, it has also been shown to have anti-cancer and longevity promoting properties ([@B25]). The drug repurposing strategy has already resulted in identification of new an antiviral agents (e.g., quinine as antiviral against dengue virus infection) ([@B36]). Further studies are warranted to confirm that this strategy applied as PT repurposing might be successful in the treatment of some viral and fungal infections.

There were observations on antiviral activity of phage in the 1960s and 70s ([@B43]). However, it has to be kept in mind that those results were achieved using non-purified phage lysates. Therefore, it cannot be excluded that the observed effects were caused by bacterial remains rather than phage themselves.

It was demonstrated that *Escherichia coli* K12 phage was active against herpes simplex virus (HSV) and vaccinia virus *in vitro* (plaque inhibition assay on chick embryo monolayer cultures) and *in vivo* (a herpetic corneal ulcer model in rabbit). An antiviral agent (named, "phagicin") is a product of phage replication; it is produced and can be detected before whole infective phage particles are released from bacterial cells. It could also be obtained by disruption of phage particles and is specific against HSV and vaccinia virus. Phagicin is sensitive to trypsin and pepsin but not deoxyribonuclease, ribonuclease and ultraviolet irradiation. Therefore, phagicin appears to be a phage protein interfering with the intracellular replication of viral DNA ([@B11]). Those data were confirmed by Meek et al., indicating that "phagicin" inhibits the synthesis of viral DNA but not the host DNA ([@B38]). In addition, [@B40] showed similar action for phage lambda. Those and other available data have been summarized ([@B43]). Phage anti-viral action may be mediated via their nucleic acids as well as competition of phage and eukaryotic viruses for the same cellular receptors. Phage proteins have been shown to cause adjuvant-like action. Furthermore, phage may inhibit reactive oxygen species production relevant in the pathology of viral infections, Those phage-mediated effects may enhance anti-viral responses ([@B44]; [@B19]). This list does not exclude other possible mechanisms which remain largely unexplored, such as phage action at the level of natural killer (NK) cells. That indeed those findings may have some clinical significance and offer hope for their therapeutic potential is confirmed by our observations of increased protection against viral infections in patients who had completed PT ([@B72]). Correction of immunodeficiency with enhanced immunity to infections as a result of PT has also been reported by Russian authors ([@B33]). Moreover, a staphylococcal phage preparation was indicated for the treatment of viral warts, HSV types 1 and 2 and other viral conditions ([@B22]).

Phage as a Potential Anti-Viral Agent
=====================================

Phage Downregulate NF-kappaB Activation
---------------------------------------

NF-kappa B transcription factors regulate the expression of genes involved in immune responses. To replicate and persist within their hosts, viruses have evolved strategies to exploit NF kappa B signaling for their benefit and avoid cellular mechanisms that eliminate the infection; in fact, its activation is a prerequisite for some viral infections ([@B49]; [@B75]; [@B69]). In contrast to HSV-1, T4 phage does not cause significant activation of NF-kappa B in human endothelial and epithelial cells. Moreover, preincubation of these cells with phage abolishes (endothelium) or significantly reduces (epithelium) NF kappa B activation ([@B21]). Interestingly, recently [@B74] confirmed and extended those findings by demonstrating that a staphylococcal phage can also abolish NF-kappa B activation by mechanisms unrelated to its anti-bacterial action. Those data may suggest that phage can inhibit NF kappa B activation triggered by different mechanisms. In our experiments phage interfered with HSV-induced mediator activation, whilst in those described by [@B74]. Lipopolysaccharide (LPS) was used as an activator ([@B21]; [@B74]). Further studies are necessary to determine whether the ability of phage to inhibit NF-kappa B activation depends on phage type and /or mechanisms of mediator activation.

The fact that a staph phage also inhibits activation of NF kappa B ([@B74]) indicates that this is not a unique property of T4 phage. Although there are no data available on similar activities of purified phage proteins, some of those proteins have been demonstrated to mediate anti-inflammatory effects similar to functional phage ([@B45]). Moreover, immobilized T4 phage show adhesive interactions with human T cells which can also be observed using purified gp24 phage protein ([@B17]). Nevertheless, currently available data are very scarce and further studies on the structure and immunobiological activities of phage proteins would shed more light on their potential application in therapy. Interestingly, in experiments reported by [@B71] *Staphylococcus aureus* and *Pseudomonas aeruginosa* phage induced a highly comparable (although not identical) responses of the immune system. The authors hypothesize that modular nature of phage genomes and associated similar folds of phage capsid proteins may be responsible for those similarities. For example, gp23 and gp24 capsid proteins of *E. coli* phage T4 have a similar fold as that of the *E. coli* phage HK97 capsid protein. A single point mutation can change the serotype of the phage. The authors suggest that this might also be true for two *P. aeruginosa* phage that are homologous and only slightly differ in the induced immune response.

### Lysogenic Conversion and Immune Response

Phage-dependentinhibition of NF-kappa B activity mentioned above was brought about by virulent phage. Furthermore, immunomodulatory effects reported by [@B71] have also been mediated by such phage. On the other hand, phagicin production required induction of the lysogenic strain. No data are available on similar activities mediated by temperate phage. Interestingly, recent data from the Fischetti group have provided evidence that lysogeny plays a major role in the human adaptive immune response to bacterial infection. In those studies, prophages were shown to be responsible for a strong T and B cell immune response to lysogenic strains of bacteria ([@B65]). In contrast, lysogenic conversion has been shown to decrease phagocytosis of bacteria by phagocytes ([@B70]; [@B63]). Thus, associations between lysogeny and immunity are complex and require further studies.

Phage Inhibit Adsorption and Replication of Human Adenovirus and Modify the Expression of Genes Involved in Antimicrobial Immunity
----------------------------------------------------------------------------------------------------------------------------------

In the first studies on the effect of phage on stages of infection by a pathogenic virus we found substantial dose-dependent inhibition by T4 phage of adsorption of HAdV to both A549 and HEK293 cell lines *in vitro* LPS was without effect. Moreover, T4 phage protected A549 cells from an HAdV-induced cytopathic effect ([@B42]; [@B53]). These data suggest that T4 phage could be considered as a potential novel antiviral agent. The capacity of the phage to inhibit HAdV infection at the stage of viral replication suggests that phage could also interfere with viruses using cellular receptors other than those used by HAdV. Notably, the anti-viral effect of phage was measured as the decrease of the end-point HAdV infectious titer. Further *in vitro* studies were carried out on the effects of T4 and the staphylococcal phage A5/80 on HAdV DNA synthesis (real-time PCR) and the expression of its early and late genes (measured at the level of mRNA synthesis) in an A549 cell culture. Continuous incubation of adenovirus-infected cells with T4 phage significantly reduced the level of adenoviral DNA synthesis (this effect was not observed with the staphylococcal phage). Coincubation with a high titer of T4 phage was required for inhibition of HAdV early gene expression. Late adenoviral gene expression was reduced by preincubation (application of phage prior to HAdV infection) and coincubation with both phage when a low HAdV titer was used. In contrast, when a high HAdV titer was applied, both incubation and preincubation with T4 phage were inhibitory whilst a staphylococcal phage was inhibitory only when continuous incubation with cells was applied. Those results suggest that the inhibitory effect of phage on HAdV infection may differ and may be partially explained by their influence on the expression of early and late adenoviral genes ([@B54]). When the effect of both phage on the expression of genes involved in antimicrobial immunity by the A549 cell line from human lung was studied, the most striking phenomenon was marked (\>10-fold) enhancement of a gene coding for interleukin-2 (Il-2) by a staphylococcal phage ([@B6]). This effect is of particular interest in the context of the well-known role of NK cells in the immune response to viruses ([@B26]) and the ability of Il-2 to induce those cells -- even in ultra-low doses ([@B14]; [@B28]). Interestingly, a resident NK cell population is present in the human lung and may provide early and important control of viral infection ([@B12]). Moreover, NK cells also exhibit activity against a variety of bacteria, e.g., by secretion of the soluble molecules perforin and granulysin. Mice infected with *Shigella* and lacking B and T cells but with normal NK cells have higher survival rates and lower bacterial titers than mice which lack all three cell types. This suggests that phage-induced Il-2 dependent activation of NK-mediated antimicrobial activity may contribute to beneficial effects of PT, especially during prolonged phage administration cumulative median duration of successful phage therapy is 43 days ([@B41]). NK cells could be a promising agent in antimicrobial immunotherapy, as data strongly suggest that these cells are active against not only viral but also bacterial and fungal pathogens ([@B61]).

Phage as a Potential Anti-Fungal Agent
======================================

Filamentous Phage and Inhibition of Fungal Metabolism
-----------------------------------------------------

There are some suggestions that bacteriophage may adversely impact fungal growth. These studies involve a bacteriophage produced by *P. aeruginosa* (*Pa*), a Gram negative bacteria, and the fungal pathogens *A. fumigatus* (*Af*) and *Candida albicans* (*Ca*).

*Pa* is known to have complex and clinically relevant interactions with *Af*, most notably in lung infections in patients with Cystic Fibrosis (CF). *Pa* ([@B23]; [@B4]; [@B27]) and *Af* ([@B1]; [@B3]; [@B30]) are among the most common bacterium and fungus infecting airways in CF, respectively. Both organisms are associated with more rapid declines in CF pulmonary function ([@B62]; [@B48]; [@B66]; [@B15]; [@B67]; [@B56]) and can cause invasive disease ([@B73]; [@B9]; [@B51]) as well as other complications ([@B68]; [@B7]; [@B16]). Co-colonization of the lungs of CF patients with *Pa* and *Af* can result in more severe pulmonary disease. However, *Pa* can be inhibitory to *Af* through the production of multiple antimicrobials such as pyocyanin (5-N-methyl-1-hydroxyphenazine) ([@B37]; [@B5]; [@B31]; [@B8]), 1-hydroxyphenazine ([@B37]; [@B31]; [@B8]), and phenazine-1-carboxamide and phenazine-1-carboxylic acid ([@B8]). This inhibition is most closely associated with small colony variants of Pa although there is considerable heterogeneity between isolates ([@B2]).

Recently, it was reported that these interactions between *Pa* and *Af* are mediated in part by Pf, a filamentous bacteriophage in the genus Inovirus. Pf is prevalent amongst clinical *Pa* isolates, ([@B55]) including epidemic strains ([@B32]). Pf exists as a prophage within *Pa* and is produced in large quantities within *Pa* biofilms ([@B58]; [@B64]).

In a series of elegant studies led by Dr. David Stevens at Stanford, it was reported that Pf phage *Pa* inhibits *Af* biofilms. Pf phage produced by *Pa* binds iron and can sequester this critical resource in ways that deny it to *Af*, thereby restricting fungal growth ([@B52]). Iron concentrations are known to impact the severity of CF lung infections ([@B57]) and Fe^3+^ is a critical resource for *Af* ([@B47]). We reported that supplemental iron could overcome Pf4-mediated inhibition of *Af* metabolism and we demonstrated that Pf4 binds iron ([@B52]). This finding was consistent with previous reports that supplemental iron also overcame the inhibition seen with *Pa* supernatants ([@B68]). It was also consistent with other work suggesting that *Af* is exquisitely sensitive to the concentration of iron in the surrounding milieu ([@B47]). A similar inhibitory effect of Pf4 phage was observed on the *in vitro* growth of another fungal species, *Candida albicans* ([@B46]).

Interestingly, the ability of Pf phage to sequester iron and limit the growth of Af was limited to some phage strains and not others. Inhibition of *Af* metabolism was seen with Pf4 from *Pa* strain PA01 but not with other filamentous phage tested, including fd, from *E. coli*, and Pf1, and from *Pa* strain PAK. Consistent with this difference, Pf4 was found to bind iron more efficiently than Pf1. Some of this Pf4-Pf1 difference may perhaps reflect the greater length and proportionately increased charge area of Pf4 ([@B55]). This ability to sequester iron may therefore be specific to only some filamentous phage and the broader relevance of these findings is therefore unknown.

However, there are additional levels of complexity to these interactions. In subsequent studies, Stevens and his colleagues reported that pyoverdine likewise chelates iron and denies this resource to *Af* ([@B63]; [@B60]). However, the relative importance of these mechanisms and the impact of Pf levels on these effects are unknown. Moreover, *Pa* are known to produce multiple other molecules that are inhibitory to *Af* ([@B37]; [@B5]; [@B31]; [@B8]).

Together these results highlight the potential impact and substantial uncertainties inherent in using bacteriophage to influence fungal communities colonizing sites of chronic infection.

Conclusion
==========

The data presented in this article are still preliminary. Nevertheless, they suggest novel avenues for further research on phage immunobiology. It is rather evident that in the face of growing antibiotic resistance anti-bacterial action of phage offers the best perspectives for their therapeutic application. At any rate, it cannot be excluded that -- according to the drug repurposing strategy -- there may exist prospects for phage application unrelated to their anti-bacterial action. Further studies are necessary to determine whether PT may also bring some benefits in viral and fungal infections.
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